Heart Failure - Pipeline Insight, 2025
Description
DelveInsight’s, “Heart Failure - Pipeline Insight, 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Heart Failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Heart Failure: Overview
Heart failure (HF) is a syndrome caused by structural and functional defects in myocardium resulting in impairment of ventricular filling or the ejection of blood. The most common cause for HF is reduced left ventricular myocardial function. Major pathogenic mechanisms leading to HF are increased hemodynamic overload, ischemia-related dysfunction, ventricular remodeling, excessive neuro-humoral stimulation, abnormal myocyte calcium cycling, excessive or inadequate proliferation of the extracellular matrix, accelerated apoptosis and genetic mutations. The common symptoms of congestive heart failure include fatigue, dyspnea, swollen ankles, and exercise intolerance, or symptoms that relate to the underlying cause. Patients with heart failure present with a variety of symptoms, most of which are non-specific. The accuracy of diagnosis by presenting clinical features alone, however, is often inadequate, particularly in women and elderly or obese patients. Mortality risk increases with each subsequent HF hospitalization. The presence of repeated hospitalizations, unplanned acute visits for HF decompensating, or complicated can suggest advanced HF.
The most important consideration when categorizing heart failure is whether left ventricular ejection fraction (LVEF) is preserved or reduced (less than 50 percent). A reduced LVEF in systolic heart failure is a powerful predictor of mortality. As many as 40 to 50 percent of patients with heart failure have diastolic heart failure with preserved left ventricular function. Patients with diastolic heart failure are more likely to be women, to be older, and to have hypertension, atrial fibrillation, and left ventricular hypertrophy/ Compared with systolic heart failure, which has well-validated therapies, diastolic heart failure lacks evidence-based treatment recommendations. There is no difference in survival between diastolic and systolic heart failure that cannot be attributed to ejection fraction.
The evaluation for HF is performed using various parameters like: physical examination to determine the presence of clinical symptoms and signs, blood tests, including complete blood count, urinalysis, complete metabolic profile for levels of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, fasting lipid profile, liver function tests and thyroid-stimulating hormone. Other HF-specific laboratory tests include brain natriuretic peptide (BNP) with 70% sensitivity and 99% specificity and N-terminal proBNP (NT-proBNP) with 99% sensitivity and 85% specificity.
Considerable advances have been made in the drug treatment of heart failure over the past few decades. Spironolactone, angiotensin-converting enzyme inhibitors (ACEIs), and β-blockers are the only agents that have been shown to reduce heart failure mortality, and all are now widely used in the community. There are a number of agents in the early stage of development, which may have a potential role in the management of CHF.
""Heart Failure - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart Failure pipeline landscape is provided which includes the disease overview and Heart Failure treatment guidelines. The assessment part of the report embraces, in depth Heart Failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Heart Failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Heart Failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Heart Failure Emerging Drugs
Further product details are provided in the report……..
Heart Failure: Therapeutic Assessment
This segment of the report provides insights about the different Heart Failure drugs segregated based on following parameters that define the scope of the report, such as:
Heart Failure: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heart Failure therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heart Failure drugs.
Heart Failure Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Heart Failure: Overview
Heart failure (HF) is a syndrome caused by structural and functional defects in myocardium resulting in impairment of ventricular filling or the ejection of blood. The most common cause for HF is reduced left ventricular myocardial function. Major pathogenic mechanisms leading to HF are increased hemodynamic overload, ischemia-related dysfunction, ventricular remodeling, excessive neuro-humoral stimulation, abnormal myocyte calcium cycling, excessive or inadequate proliferation of the extracellular matrix, accelerated apoptosis and genetic mutations. The common symptoms of congestive heart failure include fatigue, dyspnea, swollen ankles, and exercise intolerance, or symptoms that relate to the underlying cause. Patients with heart failure present with a variety of symptoms, most of which are non-specific. The accuracy of diagnosis by presenting clinical features alone, however, is often inadequate, particularly in women and elderly or obese patients. Mortality risk increases with each subsequent HF hospitalization. The presence of repeated hospitalizations, unplanned acute visits for HF decompensating, or complicated can suggest advanced HF.
The most important consideration when categorizing heart failure is whether left ventricular ejection fraction (LVEF) is preserved or reduced (less than 50 percent). A reduced LVEF in systolic heart failure is a powerful predictor of mortality. As many as 40 to 50 percent of patients with heart failure have diastolic heart failure with preserved left ventricular function. Patients with diastolic heart failure are more likely to be women, to be older, and to have hypertension, atrial fibrillation, and left ventricular hypertrophy/ Compared with systolic heart failure, which has well-validated therapies, diastolic heart failure lacks evidence-based treatment recommendations. There is no difference in survival between diastolic and systolic heart failure that cannot be attributed to ejection fraction.
The evaluation for HF is performed using various parameters like: physical examination to determine the presence of clinical symptoms and signs, blood tests, including complete blood count, urinalysis, complete metabolic profile for levels of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, fasting lipid profile, liver function tests and thyroid-stimulating hormone. Other HF-specific laboratory tests include brain natriuretic peptide (BNP) with 70% sensitivity and 99% specificity and N-terminal proBNP (NT-proBNP) with 99% sensitivity and 85% specificity.
Considerable advances have been made in the drug treatment of heart failure over the past few decades. Spironolactone, angiotensin-converting enzyme inhibitors (ACEIs), and β-blockers are the only agents that have been shown to reduce heart failure mortality, and all are now widely used in the community. There are a number of agents in the early stage of development, which may have a potential role in the management of CHF.
""Heart Failure - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart Failure pipeline landscape is provided which includes the disease overview and Heart Failure treatment guidelines. The assessment part of the report embraces, in depth Heart Failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Heart Failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Heart Failure R&D. The therapies under development are focused on novel approaches to treat/improve Heart Failure.
This segment of the Heart Failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Heart Failure Emerging Drugs
- Rexlemestrocel-L: Mesoblast
- HU 6: Rivus Pharmaceuticals
- HS-001: Heartseed Inc
- Ribonucleotide reductase based gene therapy: StemCardia
Further product details are provided in the report……..
Heart Failure: Therapeutic Assessment
This segment of the report provides insights about the different Heart Failure drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Heart Failure
- There are approx. 70+ key companies which are developing the therapies for Heart Failure. The companies which have their Heart Failure drug candidates in the most advanced stage, i.e. phase III include, Mesoblast.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Heart Failure: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heart Failure therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heart Failure drugs.
Heart Failure Report Insights
- Heart Failure Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Heart Failure drugs?
- How many Heart Failure drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Heart Failure?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Heart Failure therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Heart Failure and their status?
- What are the key designations that have been granted to the emerging drugs?
- Mesoblast
- Rivus Pharmaceuticals
- Heartseed Inc
- StemCardia
- Eli Lilly and Company
- BioCardia
- Bristol Myers Squibb
- Sardocor Corp.
- AstraZeneca
- Tenaya Therapeutics
- Salubris Bio therapeutics
- Moderna Therapeutics
- Cytokinetics
- Eli Lilly and Company
- Applied Therapeutics
- Help Therapeutics
- Stealth BioTherapeutics
- Actelion Pharmaceuticals
- Bayer HealthCare Pharmaceuticals/Merck & Co
- Servier
- Lexicon Pharmaceuticals
- Windtree Therapeutics
- Rexlemestrocel-L
- HU 6
- HS-001
- Ribonucleotide reductase based gene therapy
- Tirzepatide
- CardiALLO cell therapy
- Mavacamten
- SRD-001
- AZD9977
- TN 301
- JK07
- mRNA 0184
- Omecamtiv mecarbil
- Neuregulin 4 agonist
- Caficrestat
- HiCM 188
- Elamipretide
- Macitentan
- Vericiguat
- Ivabradine
- Sotagliflozin
- Research programme: sarcoplasmic reticulum calcium transporting ATPase stimulants
Table of Contents
240 Pages
- Introduction
- Executive Summary
- Heart Failure : Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Heart Failure – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Rexlemestrocel-L: Mesoblast
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- HU 6: Rivus Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- HS-001: Heartseed Inc
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Ribonucleotide reductase based gene therapy: StemCardia
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Heart Failure Key Companies
- Heart Failure Key Products
- Heart Failure - Unmet Needs
- Heart Failure - Market Drivers and Barriers
- Heart Failure - Future Perspectives and Conclusion
- Heart Failure Analyst Views
- Heart Failure Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
